Better, faster & safer therapeutic antibody discovery. We are changing the process with AI-based solutions
AI-based docking and affinity prediction allow us to design antibodies on predetermined epitopes, chosen to trigger the desired biological effect, and high efficacy.
We evaluate inter-molecular (off-targets) and inter-species reactivity, in order to limit the side effects (cross-reactivity) and anticipate binding for pre-clinical development (cross-specificity).
Antibodies sequences liabilities (PTMs, aggregation motifs...) are evaluated during the molecular design, to optimize stability and limit immunogenicity.
Get fully characterized, high-affinity and epitope-specific humanized antibodies against your target in 21 days.
Lead candidates design in 21 days allows you to strengthen, parallelize and multiply your discovery programs.
Do not risk to spend months never finding a good lead. Know fast, retry fast and succeed fast!
No back-and-forth optimization of your hits. Start immediately with the lead candidates that are ready for development.
Combining expertises is key: computational science, biology and software development are essential skills at MAbSilico
Vincent holds a PhD in biology and worked in biotech and public research institutes in Europe before founding MAbSilico.
Thomas holds a PhD in structural biology and computer sciences. He worked on implementing AI approaches in genomics, docking, immuno-oncology.
Astrid holds a PhD in cellular biology. She worked on GPCRs mechanisms of action and their modulation by antibodies.
Anne holds a PhD in Biomathematics. She's been working on protein-protein interactions at CNRS for more than 20 years.
Drop us a line if you want to know more about our technology or if you are willing to talk about your projects. We are always keen on discussing science!
